Losartan/ja: Difference between revisions
Losartan/ja
Created page with "{{Merck&Co}} {{Angiotensin II receptor antagonists/ja}} {{Angiotensin receptor modulators/ja}} {{Portal bar | Medicine}}" |
Created page with "== さらに読む == * {{cite journal |vauthors=Al-Majed AR, Assiri E, Khalil NY, Abdel-Aziz HA |title=Losartan: Comprehensive Profile |journal=Profiles Drug Subst Excip Relat Methodol |volume=40 |pages=159–94 |date=2015 |pmid=26051686 |doi=10.1016/bs.podrm.2015.02.003 }} * {{cite journal |vauthors=Sica DA, Gehr TW, Ghosh S |title=Clinical pharmacokinetics of losartan |journal=Clin Pharmacokinet |volume=44 |issue=8 |pages=797–814 |date=2005 |pmid=16029066 |doi=10.21..." Tags: Mobile edit Mobile web edit |
||
| Line 197: | Line 197: | ||
</div> | </div> | ||
== 歴史 == | |||
{{Anchor|History}} | |||
{{main|Discovery and development of angiotensin receptor blockers}} | {{main/ja|Discovery and development of angiotensin receptor blockers/ja}} | ||
== さらに読む == | |||
* {{cite journal |vauthors=Al-Majed AR, Assiri E, Khalil NY, Abdel-Aziz HA |title=Losartan: Comprehensive Profile |journal=Profiles Drug Subst Excip Relat Methodol |volume=40 |pages=159–94 |date=2015 |pmid=26051686 |doi=10.1016/bs.podrm.2015.02.003 }} | * {{cite journal |vauthors=Al-Majed AR, Assiri E, Khalil NY, Abdel-Aziz HA |title=Losartan: Comprehensive Profile |journal=Profiles Drug Subst Excip Relat Methodol |volume=40 |pages=159–94 |date=2015 |pmid=26051686 |doi=10.1016/bs.podrm.2015.02.003 }} | ||
* {{cite journal |vauthors=Sica DA, Gehr TW, Ghosh S |title=Clinical pharmacokinetics of losartan |journal=Clin Pharmacokinet |volume=44 |issue=8 |pages=797–814 |date=2005 |pmid=16029066 |doi=10.2165/00003088-200544080-00003 |s2cid=41326620 }} | * {{cite journal |vauthors=Sica DA, Gehr TW, Ghosh S |title=Clinical pharmacokinetics of losartan |journal=Clin Pharmacokinet |volume=44 |issue=8 |pages=797–814 |date=2005 |pmid=16029066 |doi=10.2165/00003088-200544080-00003 |s2cid=41326620 }} | ||
== 外部リンク == | |||
{{Commons category|Metformin}} | |||
* {{cite web | title=Nitrosamine impurities in medications: Guidance | website=Health Canada | date=4 April 2022 | url=https://www.canada.ca/en/health-canada/services/drugs-health-products/compliance-enforcement/information-health-product/drugs/nitrosamine-impurities/medications-guidance.html }} | * {{cite web | title=Nitrosamine impurities in medications: Guidance | website=Health Canada | date=4 April 2022 | url=https://www.canada.ca/en/health-canada/services/drugs-health-products/compliance-enforcement/information-health-product/drugs/nitrosamine-impurities/medications-guidance.html }} | ||
{{Merck&Co}} | {{Merck&Co}} | ||